These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 30701884)

  • 21. Canakinumab for secondary prevention of atherosclerotic disease.
    Capodanno D; Angiolillo DJ
    Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
    Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
    J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-inflammatory therapies for cardiovascular disease.
    Ridker PM; Lüscher TF
    Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A perspective on targeting inflammation and cytokine actions in atherosclerosis.
    Chan YH; Ramji DP
    Future Med Chem; 2020 Apr; 12(7):613-626. PubMed ID: 32175772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease.
    McCarty S; Frishman W
    Cardiol Rev; 2014; 22(4):176-81. PubMed ID: 24618930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation in atherosclerotic cardiovascular disease.
    Shah PK; Lecis D
    F1000Res; 2019; 8():. PubMed ID: 31448091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Colchicine in Acute Coronary Syndromes.
    Vaidya K; Martínez G; Patel S
    Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colchicine: an affordable anti-inflammatory agent for atherosclerosis.
    Thompson PL; Nidorf SM
    Curr Opin Lipidol; 2018 Dec; 29(6):467-473. PubMed ID: 30320614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease.
    Viana-Huete V; Fuster JJ
    Rev Esp Cardiol (Engl Ed); 2019 Sep; 72(9):760-766. PubMed ID: 31078457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis.
    Paramel Varghese G; Folkersen L; Strawbridge RJ; Halvorsen B; Yndestad A; Ranheim T; Krohg-Sørensen K; Skjelland M; Espevik T; Aukrust P; Lengquist M; Hedin U; Jansson JH; Fransén K; Hansson GK; Eriksson P; Sirsjö A
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of interleukin 1β inhibition in cardiovascular disease.
    Qamar A; Rader DJ
    Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet.
    Abderrazak A; Couchie D; Mahmood DF; Elhage R; Vindis C; Laffargue M; Matéo V; Büchele B; Ayala MR; El Gaafary M; Syrovets T; Slimane MN; Friguet B; Fulop T; Simmet T; El Hadri K; Rouis M
    Circulation; 2015 Mar; 131(12):1061-70. PubMed ID: 25613820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities.
    Khambhati J; Engels M; Allard-Ratick M; Sandesara PB; Quyyumi AA; Sperling L
    Atherosclerosis; 2018 Sep; 276():1-9. PubMed ID: 30006321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
    Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH
    Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.